Effect of blockage of Notch1 signaling on the activation of T cellular immunity in peripheral blood mononuclear cells of patients with chronic hepatitis B

Abstract

Abstract: AIM: To investigate the influence of Notch1 signaling on expression of T-bet, Th1- and Th2-type cytokines and cytotoxic T-lymphocyte (CTL) cytotoxicity of peripheral blood mononuclear cells (PBMC) of patients with chronic hepatitis B, and analyze the possible function of Notch1 signaling on regulating the activation of T cellular immunity.METHODS: PBMC of patients with chronic hepatitis B were divided into test group, negative control group and blank control group, respectively was given anti-Notch1, IgG2b and RPMI-1640. The expression of T-bet mRNA was examined by real-time PCR, Th1-type cytokines IFN-γ,IL-2, Th2-type cytokines IL-4,IL-10 were assayed by enzyme-linked immunosorbent assay (ELISA) and CTL cytotoxicity was measured by Cytotoxicity Detection Assay (LDH).RESULTS:After Notch1 signaling of PBMC was blocked in chronic hepatitis B patients, expression of T-bet mRNA and the production of Th1-type cytokines IFN-γ,IL-2 were enhanced while Th2-type cytokines IL-4,IL-10 were decreased, and CTL cytotoxicity was enhanced, compared with the blank control groups (P<0.01).CONCLUSION: After blocking of Notch1 signaling of PBMC of chronic hepatitis B patients, the expression of T-bet mRNA and the production of Th1-type cytokines IFN-γ,IL-2 were increased, while Th2-type cytokines IL-4,IL-10 were decreased and CTL cytotoxicity was enhanced. It suggested that blockage of Notch1 signaling could activate T cellular immunity of patients with chronic hepatitis B, Notch1 signaling might contribute to immune tolerance of patients with chronic hepatitis B, perhaps related with T-bet.

Key words: Chronic hepatitis B, Notch1, T cellular immunity, T-bet, CTL

CLC Number:

R512.6

LIU Xue-ni, PEI Jin-xian, LI Xiao-liang, ZANG Guo-qing, YU Yong-sheng. Effect of blockage of Notch1 signaling on the activation of T cellular immunity in peripheral blood mononuclear cells of patients with chronic hepatitis B[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(2): 174-179.

References

[1] Radtke F, Wilson A, Mancini SJ, et al. Notch regulation of lymphocyte development and function [J]. Nat Immunol, 2004, 5(3): 247-53.
[2] Osborne BA, Minter LM. Notch signaling during peripheral T-cell activation and differentiation [J]. Nat Rev Immunol, 2007, 7(1): 64-75.
[3] Szabo SJ,Kim ST,Costa GL,et a1. A novel transcription factor, T-bet, directs Thl lineage commitment [J].Cell, 2000, 100(6):655-669.
[4] Szabo SJ, Sullivan BM, Stemmann C, et al .Distinct effects of T-bet in Th1 lineage commitment and IFN2 gamma production in CD₄ and CD₈ T cell [J]. Science, 2002, 295(5553): 338-342.
[5] Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection [J]. Nat Rev Immunol, 2005, 5(3):215-229.
[6] Bcher WO, Galun E, Marcus H, et al. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the Trimera mouse [J]. Hepatology, 2000, 31(2):480-7.
[7] Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the notch signaling pathway [J]. J Cell Physiol, 2003, 194(3):237-255.
[8] Amsen D, Vlander JM, Lee GR, et al. Instruction of distinct CD₄ T helper cell fates by different Notch ligands on antigen-presenting cells [J]. Cell, 2004, 117(4):515-526.
[9] Brooks DG, Teyton L, Oldstone MB, et al. Intrinsic functional dysregulation of CD₄ T cells occurs rapidly following persistent viral infection [J]. J Virol, 2005, 79(16):10514-27.
[10]裴金仙, 臧国庆, 余永胜, 等. 乙型肝炎患者外周血CD₄⁺T细胞Notch1蛋白的表达 [J].胃肠病学和肝病学杂志, 2009, 18 (12): 1136-38.
[11]Usui T, Preiss JC, Kanno Y, et al. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription [J]. J Exp Med, 2006, 203(3):755-766.
[12]Wang SY, Yang M, Xu XP, et al. Intranasal delivery of T-bet modulates the profile of helper T cell immune responses in experimental asthma [J]. J Investig Allergol Clin Immunol, 2008, 18(5): 357-65.
[13]Lametschwandtner G, Biedermann T, Schwarzler C, et al. Sustained T-bet expression confers polarized human Th2 cell with Th1-like cytokine production and migratory capacities [J]. J Allergy Clin Immunol, 2004, 113(5):987-994.

[1]	ZHAO Wei, WU Youyang, LIN Cong, HUANG Shiwei, CHEN Hao, JIANG Wenbing. Effects of pterostilbene on myocardial function, myocardial fibrosis and inflammatory response in rats with acute myocardial infarction and on Notch1/eIF3a signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 498-504.
[2]	ZHU Linjia, YUAN Shaofei, SHANGGUAN Zongxiao, CI Xiao, ZHAO Renguo, LI Yuping. Ultrasound-microbubbles mediated microRNA-449a inhibits lung cancer cell growth via the regulation of Notch1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1385-1393.
[3]	YUAN Gang, HU Airong, HU Yaoren, ZENG Chuanli, ZHU Dedong, SHI Xiaojun. Clinical efficacy and long-term prognosis of entecavir and adefovir dipivoxil in the treatment of compensatory hepatitis B cirrhosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 170-174.
[4]	HUANG Xiaolu, MA Xudong, LU Quanyi. Effects of silencing NOTCH1 gene by eukaryotic vector in multiple myeloma RPMI 8226 cell line [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 978-983.
[5]	CHEN Yonghua, CAO Qunfen, HONG Qiongyi, WANG Shumin. Effect of tenofovir disoproxil fumarate on serum FGF-23，β2-MG，Cys-C and RBP level in patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 799-804.
[6]	YU Yong-sheng, WU Hao, TANG Zheng-hao, ZANG Guo-qing. Effect of silencing CTLA4 with siRNA on the Th1/Th2 cytokines in peripheral blood of chronic hepatitis B patient [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 553-557.
[7]	PENG Guan-qing, ZHANG Chang, LIU Xue-feng. Clinical character of patients relapsed after withdrawal with lamivudine therapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(10): 1166-1169.
[8]	ZHU Yue-ke, DUAN Zhong-ping, WANG Bao-en, SHAN Jing, CHEN Yu, HAN Da-kang, ZHAO Jun. Therapeutic effects of silybin-phosphatidylcholine compound on patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(12): 1392-1394.
[9]	YANG Huan. Guidance for the evaluation and design of clinical trials of new medicinal products in treatment of chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(2): 121-130.
[10]	LI Wen-li, WU Shi-pin. Efficacy of adefovir dipivoxil in treating patients with hepatitis B resistant to lamivudine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 832-834.
[11]	WANG Chang-sheng, XU Hui-yang, KUAI Hui-fen. Clinical evaluation on marine capsules combined with the composite Salvia miltiorrhiza dropping pill in treatment of patients with cirrhosis related to chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(5): 570-573.
[12]	LI Wen-Li. Clinical evaluation of lamivudine in treatment of patients with chronic hepatitis B and asymptomatic carriers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(2): 198-200.
[13]	ZHANG Jing-Liang, JIA Chuan-Chun, LUAN Ling. Comparison of the efficacy between stronger Neo-Minophagen C(SNMC) and caryophyllin in treatment of patients with chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(2): 207-209.
[14]	ZHANG Jing-Ling, GU Jing-Jing, WANG Tian-Dong. Clinical observation of interferon α-1b combined with oxymatrine in the treatment of chronic hepatitis B [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(4): 344-346.